Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

HIV-1 Tat promotes astrocytic release of CCL2 through MMP/PAR-1 signaling.

Bozzelli PL, Yin T, Avdoshina V, Mocchetti I, Conant KE, Maguire-Zeiss KA.

Glia. 2019 Sep;67(9):1719-1729. doi: 10.1002/glia.23642. Epub 2019 May 23.

PMID:
31124192
2.

Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies.

Caplan IF, Maguire-Zeiss KA.

Front Pharmacol. 2018 May 4;9:417. doi: 10.3389/fphar.2018.00417. eCollection 2018. Review.

3.

Inflammation alters AMPA-stimulated calcium responses in dorsal striatal D2 but not D1 spiny projection neurons.

Winland CD, Welsh N, Sepulveda-Rodriguez A, Vicini S, Maguire-Zeiss KA.

Eur J Neurosci. 2017 Nov;46(9):2519-2533. doi: 10.1111/ejn.13711. Epub 2017 Oct 10.

4.

Protease induced plasticity: matrix metalloproteinase-1 promotes neurostructural changes through activation of protease activated receptor 1.

Allen M, Ghosh S, Ahern GP, Villapol S, Maguire-Zeiss KA, Conant K.

Sci Rep. 2016 Oct 20;6:35497. doi: 10.1038/srep35497.

5.

Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders.

Daniele SG, Béraud D, Davenport C, Cheng K, Yin H, Maguire-Zeiss KA.

Sci Signal. 2015 May 12;8(376):ra45. doi: 10.1126/scisignal.2005965.

6.

From student to steward: the Interdisciplinary Program in Neuroscience at Georgetown University as a case study in professional development during doctoral training.

Ullrich L, Dumanis SB, Evans TM, Jeannotte AM, Leonard C, Rozzi SJ, Taylor CM, Gale K, Kanwal JS, Maguire-Zeiss KA, Wolfe BB, Forcelli PA.

Med Educ Online. 2014 Jul 7;19:22623. doi: 10.3402/meo.v19.22623. eCollection 2014.

7.

The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.

Savolainen MH, Richie CT, Harvey BK, Männistö PT, Maguire-Zeiss KA, Myöhänen TT.

Neurobiol Dis. 2014 Aug;68:1-15. doi: 10.1016/j.nbd.2014.04.003. Epub 2014 Apr 16.

PMID:
24746855
8.

Isolation of cortical microglia with preserved immunophenotype and functionality from murine neonates.

Daniele SG, Edwards AA, Maguire-Zeiss KA.

J Vis Exp. 2014 Jan 30;(83):e51005. doi: 10.3791/51005.

9.

Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.

Huang L, Shimoji M, Wang J, Shah S, Kamila S, Biehl ER, Lim S, Chang A, Maguire-Zeiss KA, Su X, Federoff HJ.

Neurotherapeutics. 2013 Oct;10(4):840-51. doi: 10.1007/s13311-013-0208-3.

10.

Parkinson's disease.

Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA.

Subcell Biochem. 2012;65:389-455. doi: 10.1007/978-94-007-5416-4_16. Review.

11.

Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein.

Béraud D, Hathaway HA, Trecki J, Chasovskikh S, Johnson DA, Johnson JA, Federoff HJ, Shimoji M, Mhyre TR, Maguire-Zeiss KA.

J Neuroimmune Pharmacol. 2013 Mar;8(1):94-117. doi: 10.1007/s11481-012-9401-0. Epub 2012 Oct 10.

12.
13.

Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease.

Béraud D, Maguire-Zeiss KA.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S17-20. doi: 10.1016/S1353-8020(11)70008-6. Review.

14.

α-Synuclein Alters Toll-Like Receptor Expression.

Béraud D, Twomey M, Bloom B, Mittereder A, Ton V, Neitzke K, Chasovskikh S, Mhyre TR, Maguire-Zeiss KA.

Front Neurosci. 2011 Jun 29;5:80. doi: 10.3389/fnins.2011.00080. eCollection 2011.

15.

Dopamine and paraquat enhance α-synuclein-induced alterations in membrane conductance.

Feng LR, Maguire-Zeiss KA.

Neurotox Res. 2011 Nov;20(4):387-401. doi: 10.1007/s12640-011-9255-x. Epub 2011 Jul 7.

16.

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.

Lee BD, Shin JH, VanKampen J, Petrucelli L, West AB, Ko HS, Lee YI, Maguire-Zeiss KA, Bowers WJ, Federoff HJ, Dawson VL, Dawson TM.

Nat Med. 2010 Sep;16(9):998-1000. doi: 10.1038/nm.2199. Epub 2010 Aug 22.

17.

Alpha-synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability.

Feng LR, Federoff HJ, Vicini S, Maguire-Zeiss KA.

Eur J Neurosci. 2010 Jul;32(1):10-7. doi: 10.1111/j.1460-9568.2010.07266.x. Epub 2010 Jun 14.

18.

Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's disease.

Maguire-Zeiss KA, Federoff HJ.

J Neural Transm (Vienna). 2010 Aug;117(8):1019-25. doi: 10.1007/s00702-010-0431-6. Epub 2010 Jun 12. Review.

PMID:
20549523
19.

Gene therapy in Parkinson's disease: rationale and current status.

Feng LR, Maguire-Zeiss KA.

CNS Drugs. 2010 Mar;24(3):177-92. doi: 10.2165/11533740-000000000-00000. Review.

20.

Mutant alpha-synuclein overexpression mediates early proinflammatory activity.

Su X, Federoff HJ, Maguire-Zeiss KA.

Neurotox Res. 2009 Oct;16(3):238-54. doi: 10.1007/s12640-009-9053-x. Epub 2009 Apr 28.

Supplemental Content

Loading ...
Support Center